In:
Journal of the American Heart Association, Ovid Technologies (Wolters Kluwer Health), Vol. 12, No. 24 ( 2023-12-19)
Abstract:
Cardiac hypertrophy (CH) is a well‐established risk factor for many cardiovascular diseases and a primary cause of mortality and morbidity among older adults. Currently, no pharmacological interventions have been specifically tailored to treat CH. OTUD7B (ovarian tumor domain‐containing 7B) is a member of the ovarian tumor‐related protease (OTU) family that regulates many important cell signaling pathways. However, the role of OTUD7B in the development of CH is unclear. Therefore, we investigated the role of OTUD7B in CH. Methods and Results OTUD7B knockout mice were used to assay the role of OTUD7B in CH after transverse aortic coarctation surgery. We further assayed the specific functions of OTUD7B in isolated neonatal rat cardiomyocytes. We found that OTUD7B expression decreased in hypertrophic mice hearts and phenylephrine‐stimulated neonatal rat cardiomyocytes. Furthermore, OTUD7B deficiency exacerbated transverse aortic coarctation surgery‐induced myocardial hypertrophy, abnormal cardiac function, and fibrosis. In cardiac myocytes, OTUD7B knockdown promoted phenylephrine stimulation‐induced myocardial hypertrophy, whereas OTUD7B overexpression had the opposite effect. An immunoprecipitation–mass spectrometry analysis showed that OTUD7B directly binds to KLF4 (Krüppel‐like factor 4). Additional molecular experiments showed that OTUD7B impedes KLF4 degradation by inhibiting lysine residue at 48 site‐linked ubiquitination and suppressing myocardial hypertrophy by activating the serine/threonine kinase pathway. Conclusions These results demonstrate that the OTUD7B‐KLF4 axis is a novel molecular target for CH treatment.
Type of Medium:
Online Resource
ISSN:
2047-9980
DOI:
10.1161/JAHA.123.029745
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2023
detail.hit.zdb_id:
2653953-6
